Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14965206 | 0.85 | SMN1; SMN2 (0.61) | KDM4ETP53SMN1; SMN2ADRB3NPSR1 | |
| SCHEMBL16293998 | 0.84 | SMN1; SMN2 (0.51) | SMN1; SMN2 | |
| SCHEMBL14970182 | 0.84 | SMN1; SMN2 (0.47) | SMN1; SMN2 | |
| SCHEMBL14965472 | 0.84 | SMN1; SMN2 (0.49) | KDM4ETP53SMN1; SMN2ADRB3 | |
| SCHEMBL14965047 | 0.83 | ALDH1A1 (0.55) | KDM4ETP53SMN1; SMN2 | |
| SCHEMBL14965029 | 0.83 | KDM4E (0.51) | KDM4ETP53SMN1; SMN2NPSR1 | |
| SCHEMBL14965339 | 0.82 | LMNA (0.67) | ADRB3 | |
| SCHEMBL14965394 | 0.82 | KDM4E (0.48) | KDM4ETP53SMN1; SMN2 | |
| SCHEMBL14965235 | 0.81 | LMNA (0.68) | KDM4ETP53SMN1; SMN2NPSR1 | |
| SCHEMBL14964732 | 0.78 | SMN1; SMN2 (0.55) | KDM4ETP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152634-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | XENTION LTD (GB) | 2016-06-02 | — | — | US | disclosed |
| US-9290511-B2 | Thieno-pyrimidines, useful as potassium channel inhibitors | XENTION LIMITED (GB) | 2016-03-22 | — | — | US | disclosed |
| US-20140371203-A1 | Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors | XENTION LIMITED (GB) | 2014-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371203-A1 | Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors | KCNA3, KCNJ1, KCNJ11 | KDM4E 897/4885TP53 3312/4885SMN1; SMN2 3639/4885 |
| US-20160152634-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | KCNA3, KCNJ1, KCNJ11 | KDM4E 809/4885TP53 3340/4885SMN1; SMN2 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.